首页> 美国卫生研究院文献>Journal of Enzyme Inhibition and Medicinal Chemistry >Osteopontin – a biomarker of disease but also of stage stratification of the functional myocardial contractile deficit by chronic ischaemic heart disease
【2h】

Osteopontin – a biomarker of disease but also of stage stratification of the functional myocardial contractile deficit by chronic ischaemic heart disease

机译:骨桥蛋白-疾病的生物标志物也是慢性缺血性心脏病导致的功能性心肌收缩缺陷的阶段分层

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The study analyses the significance of the plasmatic values of the OPN dosed to 91 people suffering from diastolic cardiac dysfunction with preserved ejection fraction, thus revealing significant growths of its level compared to the normal value. Despite being a clinical research, its conclusions are a breakthrough, differing from the results of other studies published in the relevant medical literature. We can make this assertion because this study analyses the clinical information given by the circulating values of the OPN, based on experimental models (animals), or on patients with congestive heart failure, which can be identified with the existence of a low systolic flow. The results of our study allow us to assert that the plasmatic values of this glycoprotein lead to its acceptance in the medical practice as a new biomarker that provides indicators regarding the stratification of risk with the patients suffering from heart failure of the diastolic dysfunction type, but whose systolic flow is preserved.
机译:这项研究分析了91例患有舒张性心脏功能不全且射血分数保留的人的OPN血浆值的意义,从而揭示了其水平较正常值有显着增长。尽管是一项临床研究,其结论还是一个突破,与相关医学文献中发表的其他研究结果不同。我们之所以可以这样说,是因为这项研究根据实验模型(动物)或充血性心力衰竭患者分析了OPN循环值所提供的临床信息,这些患者可以被认为存在低的收缩压。我们的研究结果使我们能够断言,这种糖蛋白的血浆价值导致其在医学实践中被接受为一种新的生物标志物,它提供了有关舒张功能障碍类型心力衰竭患者的危险分层的指标,但是保留其心脏收缩流量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号